We are live on ! Find out more
FP

Flagship Pioneering Portfolio holdings

AUM $1.54B
1-Year Est. Return 86.39%
This Fund
S&P 500
This Quarter Est. Return
+33.2%
1 Year Est. Return
+86.39%
3 Year Est. Return
-13.28%
5 Year Est. Return
-50.7%
10 Year Est. Return
+414.55%
AUM
$1.54B
AUM Growth
+$378M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
5
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GENB
1
Generate Biomedicines
GENB
$2.1B
$1.06B 68.66%
62,673,117
MRNA icon
2
Moderna
MRNA
$58.1B
$324M 21.07%
4,632,149
SANA icon
3
Sana Biotechnology
SANA
$1.15B
$87.3M 5.67%
25,001,856
FHTX icon
4
Foghorn Therapeutics
FHTX
$292M
$61.8M 4.02%
12,674,120
MCRB icon
5
Seres Therapeutics
MCRB
$57.5M
$9.12M 0.59%
1,155,850

Similar funds

Flagship Pioneering's Q2 2026 Portfolio in Review

As of Q2 2026, Flagship Pioneering held 5 positions worth $1.54B, up 33% from $1.16B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2026: portfolio turnover was 0%. Flagship Pioneering opened no new positions and made no exits, leaving the 5-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Flagship Pioneering's ten largest holdings make up 100% of its $1.54B portfolio in Q2 2026.
  • Flagship Pioneering opened 0 new positions and closed 0 in Q2 2026.
  • Flagship Pioneering's portfolio value rose 33% quarter-over-quarter to $1.54B.

Based on Flagship Pioneering's 13F filing for Q2 2026, filed 14 Aug 2026.